AliveDx, a global leader in in vitro diagnostics, recently introduced LumiQ™, an automated immunofluorescence assay (IFA) solution designed to revolutionize the diagnosis of autoimmune diseases. This new addition to the company’s portfolio, along with the innovative MosaiQ technology® planar chip, provides customers with a comprehensive and differentiated solution for faster and more accurate diagnosis.
Recognized as the gold standard for detecting antinuclear antibodies in autoimmune diseases, LumiQ offers laboratories a powerful tool to enhance diagnostic capabilities, improve efficiency, and increase reliability. By automating every step of the IFA workflow, from slide preparation to image capture, LumiQ ensures uptime and provides recommendations for positive and negative classification as well as pattern interpretation with excellent confidence. This not only helps specialists interpret IFA results with ease but also contributes to consistency and reduces human error.
The MosaiQ platform, a fully automated, high-throughput platform that streamlines multiplex testing for autoimmune and other diseases, complements LumiQ for comprehensive autoimmune disease diagnostics. Together, these platforms meet the growing expectations for laboratory efficiency by offering advanced technology and automation.
AliveDx, with over 30 years of experience in in vitro diagnostics, is dedicated to advancing diagnostic knowledge, transforming patient care, and innovating for life. The company’s mission is to create innovative solutions that accelerate the time to diagnosis, simplify lab workflows, and deliver fast, accurate results to support clinical decision-making. AliveDx collaborates with labs, clinicians, patient advocacy groups, academic institutions, and industry partners to bring purpose, meaning, and energy to communities worldwide.
For more information about AliveDx and its in vitro diagnostic solutions, visit their website at http://www.alivedx.com. Join the conversation on LinkedIn and stay updated on the latest developments in diagnostic technology and patient care.
As a leading magazine editor, we are excited to see AliveDx’s commitment to transforming patient care through innovative solutions like LumiQ and MosaiQ. These advancements in diagnostic technology are poised to make a significant impact on the diagnosis and treatment of autoimmune diseases, ultimately improving patient outcomes and driving efficiency in laboratory operations. Visit AliveDx’s website to learn more about their cutting-edge solutions and how they are innovating for life.
Source link
